Immunological and molecular assessment of HIV-1 mutations for antiretroviral drug resistance in Saudi Arabia

Human Immunodeficiency Virus (HIV) is a significant threat to public health. HIV genotyping and antiretroviral resistance testing may have contributed to improved non-treated management. Immune markers might assist HIV-1 diagnosis and drug-resistant variant identification. HIV-1 immunogenicity and molecular characteristics of antiretroviral drug resistance are evaluated in 56 treatment-naive HIV patients. DNA sequencing and retroviral resistance testing identified HIV-1 genotypes. 55.4% of patients were susceptible to protease inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTI), and non-nucleoside reverse transcriptase inhibitors (NNRTI) antiretroviral drugs, whereas 44.6% had drug-resistance mutations against at least one antiretroviral drug. 3.6% of cases had PI-resistant mutations, while 30.4% had NRTI-resistant mutations, and 30.4% had NNRTI-resistant mutations. In patients who are susceptible to PI, the mean value of human plasma sCD80 is 2.11 +/- 0.65 ng/mL; in patients with mutations, it is 3.93 +/- 2.91 ng/mL. Individuals who are susceptible to PI have plasma sCD27 levels of 78.7 +/- 63.2 U/mL, whereas individuals who are mutant have levels of 56.5 +/- 32.1 U/mL. IP-10's mean value was 363 +/- 109.2 pg/mL for the susceptible patients and 429 +/- 20.7 pg/mL for the mutated patients. In susceptible patients, the plasma sCD4 level is 0.163 +/- 0.229 ng/mL; in mutant patients, it is 0.084 +/- 0.012 ng/mL. The data showed a relative relation between immunological parameters such as sCD80, sCD27, sCD4, and IP-10 and mutation for drug resistance.